Withdrawn application: Jesduvroq, daprodustat, Date of withdrawal: 12/07/2023, Initial authorisation
GlaxoSmithKline Trading Services Limited withdrew its application for a marketing authorisation of Jesduvroq for the treatment of adult patients with symptoms of anaemia caused by chronic kidney disease. The company withdrew the application on 12 July 2023 …